News Releases:

2015

miRagen Therapeutics Initiates First Clinical Trial for Anti-Fibrosis Product Candidate MRG-201

BOULDER, Colorado, – November 12, 2015 – miRagen Therapeutics, Inc. a biopharmaceutical company developing innovative microRNA-based therapeutics, today announced that it has initiated a Phase 1 clinical study of MRG-201, a synthetic microRNA mimic (promiR) to microRNA-29b.  The Phase 1 trial... View »

miRagen Therapeutics Secures $41 million Series C Financing to Advance Two MicroRNA Programs into Clinical Trials

BOULDER, Colorado, – November 10, 2015 – miRagen Therapeutics, a biopharmaceutical company developing innovative microRNA-based therapeutics, today announced a Series C Preferred Stock financing with gross proceeds of $41 million, including conversion of outstanding notes.  miRagen plans to use the proceeds from... View »